Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer.
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Immunomedics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IMMU's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: IMMU exceeded the US Biotechs industry which returned 22.1% over the past year.
Return vs Market: IMMU exceeded the US Market which returned 3.7% over the past year.
Price Volatility Vs. Market
How volatile is Immunomedics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StAnalysts Just Shipped A Sizeable Upgrade To Their Immunomedics, Inc. (NASDAQ:IMMU) Estimates
1 month ago | Simply Wall StAre Insiders Buying Immunomedics, Inc. (NASDAQ:IMMU) Stock?
1 month ago | Simply Wall StIs Immunomedics (NASDAQ:IMMU) Using Debt Sensibly?
Is Immunomedics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IMMU ($34.47) is trading below our estimate of fair value ($75.93)
Significantly Below Fair Value: IMMU is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IMMU is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: IMMU is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMMU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMMU is overvalued based on its PB Ratio (39.6x) compared to the US Biotechs industry average (3.8x).
How is Immunomedics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMMU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMMU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMMU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMMU's revenue (60.8% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: IMMU's revenue (60.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMMU is forecast to be unprofitable in 3 years.
How has Immunomedics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMMU is currently unprofitable.
Growing Profit Margin: IMMU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMMU is unprofitable, and losses have increased over the past 5 years at a rate of -40.8% per year.
Accelerating Growth: Unable to compare IMMU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMMU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: IMMU has a negative Return on Equity (-196.31%), as it is currently unprofitable.
How is Immunomedics's financial position?
Financial Position Analysis
Short Term Liabilities: IMMU's short term assets ($561.7M) exceed its short term liabilities ($67.1M).
Long Term Liabilities: IMMU's short term assets ($561.7M) exceed its long term liabilities ($342.1M).
Debt to Equity History and Analysis
Debt Level: IMMU is debt free.
Reducing Debt: IMMU has no debt compared to 5 years ago when its debt to equity ratio was 2116.5%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMMU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IMMU has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Immunomedics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMMU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMMU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMMU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMMU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMMU's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Harout Semerjian (49yo)
Mr. Harout Semerjian has been President, Director and Chief Executive Officer of Immunomedics, Inc. since April 16, 2020. He had been an Executive Vice President at Ipsen S.A. since February 2, 2017 until ...
|Executive Chairman||no data||US$1.80m||no data|
|CFO & Chief Business Officer||1.75yrs||US$1.92m||no data|
|Chief Commercial Officer||2.5yrs||US$1.82m||no data|
|Chief Quality Officer||1.25yrs||US$2.56m||0.0043% $344.6k|
|President||0.083yr||no data||no data|
|Principal Accounting Officer||1.75yrs||no data||no data|
|Director of Administration||no data||no data||no data|
|Senior Director of Investor Relations||no data||no data||no data|
|General Counsel & Corporate Secretary||1.67yrs||US$1.84m||no data|
|Chief Human Resources Officer||1.67yrs||US$1.50m||no data|
Experienced Management: IMMU's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
|Executive Chairman||no data||US$1.80m||no data|
|President||0.083yr||no data||no data|
|Independent Director||3.17yrs||US$316.71k||no data|
|Independent Director||3.17yrs||US$342.97k||no data|
|Independent Director||1.17yrs||US$523.61k||no data|
|Independent Director||1.25yrs||US$500.92k||no data|
|Independent Director||0.25yr||no data||no data|
Experienced Board: IMMU's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.6%.
Immunomedics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Immunomedics, Inc.
- Ticker: IMMU
- Exchange: NasdaqGM
- Founded: 1982
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$7.959b
- Shares outstanding: 230.90m
- Website: https://www.immunomedics.com
Number of Employees
- Immunomedics, Inc.
- 300 The American Road
- Morris Plains
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IMMU||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Apr 1984|
|IM3||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Apr 1984|
|0J9H||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Apr 1984|
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody; and a collaboration and license agreement with pH Pharma Co. Ltd. for the development and commercialization of multiple novel antibody-drug conjugates in oncology. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/26 01:23|
|End of Day Share Price||2020/05/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.